RAIsonance, Inc. Announces BARDA Contract to Continue Development of the AudibleHealth Dx Diagnostic SaMD for COVID-19 and Influenza Through AI-Powered Cough Analysis
The contract consists of just over $749,000 allocated to the continued development of RAIsonance’s AudibleHealth Dx Diagnostic SaMD. The device is designed to analyze a user’s Forced Cough Vocalization (FCV) in the diagnosis of illness, with the current focus on both COVID-19 and Influenza.